Evidence map›Paper›PMID 40300826›Full record

ArticleJournal of the American Board of Family Medicine : JABFM2025

Evaluating Pragmatism of Lung Cancer Screening Randomized Trials with the PRECIS-2 Tool.

Erin A Hirsch, Jamie L Studts, Susan Zane, Marina McCreight, Amy G Huebschmann

Abstract read
In one paragraph

Article in Journal of the American Board of Family Medicine : JABFM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Research on the Social Context of Medicine and the Modern Family Physician.Journal of the American Board of Family Medicine : JABFM
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Erin A HirschFrom the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH). Erin.Hirsch@cuanschutz.edu).
Jamie L StudtsFrom the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH).
Susan ZaneFrom the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH).
Marina McCreightFrom the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH).
Amy G HuebschmannFrom the Cancer Prevention Precision Control Institute, Cancer for Discovery & Innovation at Hackensack Meridian Health, Nutley, NJ, and University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology, Aurora, CO (EAH); Professor, Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, Co-Leader, Cancer Prevention and Control Program, University of Colorado Cancer Center, Aurora, CO (JLS); University of Colorado School of Medicine, Department of Family Medicine, Aurora, CO (SZ); Colorado School of Public Health, Department of Health Systems Management and Policy, Aurora, CO (MM); University of Colorado School of Medicine, Department of Medicine, Division of General Internal Medicine, Adult and Child Center for Outcomes Research and Delivery Science, Ludeman Family Center for Women's Health Research, Aurora, CO (AGH).

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
NCATS NIH HHS UL1 TR002535
6 · The paper itself

Abstract

objectiveLung cancer screening (LCS) implementation has been challenging for community and rural primary care settings. One contributing factor may be that the randomized clinical trials (RCTs) that form the evidence base are guided by explanatory methods not reflective of primary care settings. This study applied the

methodsLCS RCTs were identified from efficacy meta-analyses, and the VA Demonstration Project was chosen as a nonrandomized multi-center comparator case. Two independent raters evaluated PRECIS-2 domains for each trial. Ratings were completed on a 5-point scale, where 1 indicated completely explanatory and 5 indicated completely pragmatic. Mean PRECIS-2 scores were calculated for each study and each domain. Descriptive information from raters' comments was used to describe differences between the most pragmatic and most explanatory RCTs.

resultsEleven RCTs and the VA Demonstration Project were evaluated. Mean PRECIS-2 scores for each study ranged from 2.12 to 3.33, with the DLSCT rated the most explanatory and the Lung Screening Study and ITALUNG studies rated the most pragmatic. Six domains had a mean score <3, indicating more explanatory (eligibility, recruitment, setting, organization, staff flexibility, follow-up). The remaining 3 domains had mean scores >3, indicating more pragmatic (adherence, outcome, analysis). DISCUSSION: This approach of evaluating each study from a primary care lens demonstrated that LCS RCTs trended toward a more explanatory nature, incorporating considerable support and infrastructure that extend beyond the capacity of typical primary care settings in the US.

Indexed as

Early Detection of CancerLung NeoplasmsMass ScreeningRandomized Controlled Trials as TopicHumansPrimary Health CareCancer ScreeningEarly Detection of CancerImplementation ScienceLung CancerPragmatismPreventive HealthPrimary Health Care

Identifiers

PMID40300826
PMCPMC12096383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.